Spots Global Cancer Trial Database for A Study of JAB-21822 in Patients With KRAS p.G12C Mutated Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of JAB-21822 in Patients With KRAS p.G12C Mutated Pancreatic Cancer
Official Title: A Phase 2, Multi-Center, Open-Label, Single-arm Study to Evaluate the Efficacy and Safety of JAB-21822 Monotherapy in Patients With Locally Advanced or Metastatic KRAS p.G12C Mutated Pancreatic Cancer
Study ID: NCT06008288
Interventions
Study Description
Brief Summary: This study is to evaluate the efficacy and safety of JAB-21822 monotherapy in adult participants with KRAS G12C mutated pancreatic cancer
Detailed Description: This is a single-arm, open-label, multicenter phase 2 study to evaluate the efficacy and safety of JAB-21822 monotherapy in adult participants with advanced KRAS p.G12C mutated pancreatic cancer.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
Beijing Cancer Hospital, Beijing, Beijing, China
Peking Union Medical College Hospital, Beijing, Beijing, China
Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Fujian Cancer Hospital, Fuzhou, Fujian, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
The First Affiliated Hospital of Sun, Yat-sen University, Guangzhou, Guangdong, China
Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Henan Cancer Hospital, Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Hubei Cancer Hospital, Wuhan, Hubei, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Hunan Cancer Hospital, Changsha, Hunan, China
Hunan Provincial People's Hospital, Changsha, Hunan, China
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
Jiangsu Province Hospital, Nanjing, Jiangsu, China
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
The First Hospital of China Medical University, Shenyang, Liaoning, China
Shandong Cancer Hospital, Jinan, Shandong, China
Huashan Hospital, Fudan University, Shanghai, Shanghai, China
Shanghai Changhai Hospital, Shanghai, Shanghai, China
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute＆Hospital, Tianjin, Tianjin, China
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Contact Details
Name: Jacobio Pharmaceuticals
Affiliation: Jacobio Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
